Tag Archives: IP

Biotech IP Challenges Around the World: BIO’s Special 301 Submission

satellite-image

BIO recently submitted its Special 301 Submission highlighting intellectual property (IP) challenges around the world.  In particular, BIO informed the United States Trade Representative (USTR) of the persistent problems biotech companies face with issues including counterfeiting, large backlogs and patent office inefficiency, differing judicial standards for enforcement, compulsory licensing, inadequate data protection, lack of patentability of biotech inventions, overbearing genetic resources access and benefit regimes, technology transfer issues and a great need for international harmonization Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Brazilian Innovation: A Patent Success

plant

The story of Acheflan highlights the role of patents in homegrown innovation in developing countries.  Professor Michael Ryan of George Washington University Law School reviewed several case studies (including Acheflan) in Brazil that highlight the differences in biomedical innovation both pre- and post-intellectual property reforms. In the early 1980’s, Ache Laboratorios Farmaceuticos (a Brazilian generics manufacturer) became aware of a plant that grew near coastal cities that local fishermen would mash into an oil rub Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Scientific American on BRIC’s IP Environment

Scientific American World View issued a special report at this year’s 2011 BIO International Convention that had several references to IP protections around the world but focused particularly on the BRIC countries (Brazil, Russia, India, and China).  See below for interesting takes on the IP environment in each country. China: Patently Ambiguous asserts that while “China’s intellectual property environment remains challenging at best” several involved on the ground in China believe that “there should be Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

USTR: TPP to have High IP Standards to “Stand Alongside other Treaty Agreements in the Area”

Stan McCoy, Assisant U.S. Trade Representative for Intellectual Property and Innovation, spoke at BIO’s 2011 Convention session titled The Trans-Pacific Partnership and the Importance of Intellectual Property Rights: Attracting Investment in Biotechnology.  The session covered the ongoing treaty negotiations and the relevance of different IP provisions to the biotechnology industry.  Issues of particular importance to the biotechnology industry yet to be revelead to the public include language tabled for data protection and patent linkage.  While USTR specific language is not available, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Counterfeiting: White House IP Czar Victoria Espinel on working with corporations

Victoria Espinel

White house IP Czar Victoria Espinel spoke at BIO’s 2011 International Convention in a session titled Counterfeiting: How corporations and government can work together.  She told the audience that when entering her new assignment she was surprised to find out that counterfeiting was a large problem in the United States and not just abroad. The Administration has increased enforcement in counterfeit medicines as seizures of health related counterfeits have gone up 97% from last year.  Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,